Alaunos Therapeutics Inc（TCRT）财务数据TCRTAlaunos Therapeutics Inc

Evaluating the bottom line, Alaunos Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -185.95%, provide a clear picture of how effectively TCRT converts its operational activities into shareholder value.

In the context of the broader market, TCRT competes directly with industry leaders such as CHGA and ELAB. With a market capitalization of $7.70M, it holds a leading position in the sector. When comparing efficiency, TCRT's gross margin of N/A stands against CHGA's N/A and ELAB's 7.99%. Such benchmarking helps identify whether Alaunos Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Alaunos has reported consecutive losses, with a net income of -$952,000 in Q2 2026 and a gross margin that has dropped to 0% in recent quarters, indicating severe operational challenges.